Hacked by islam_Bey imhatimi.org

Shilpa Medicare Ltd has informed BSE that the Company has received the Certificate of
Suitability of Monographs of the European Directorate for the Quality of Medicines (EDQM) for the Active Pharmaceutical Ingredient (API) Oxaliplatin EP.

Shilpa Medicare Ltd is first Company in India and fifth Company in world to get COS from EDQM for Oxaliplatin EP. With this approval the Company can penetrate the European Markets.

Therapeutic action: Treatment of metastatic rectal colon cancer after prior treatment with fluoropyrimidines in mono-chemotherapy or associated treatment.

The worldwide sales for Oxaliplatin in 2006 amounted to US$ 1.9 billion and growing at 28% per year.

Tags: Shilpa Medicare

This entry was posted on Friday, March 7th, 2008 at 9:03 am and is filed under News. You can follow any responses to this entry through the RSS 2.0 feed. You can leave a response, or trackback from your own site.